Stocktoria
Zivo Bioscience, Inc. ZIVO
OTC · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2000-10-06
Zivo Bioscience, Inc. financials (annual, from 10-K)
Bars are annual figures from 2015 to 2024; red bars are negative (a loss or cash outflow).
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $157,220 | $27,650 | $0 | $0 | $20,000 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $48,952 | $11,610 | $0 | — | — | — | — | — | — | — |
| R&D expense | $3.1M | $1.4M | $2.2M | $2.0M | $3.8M | $2.3M | $2.8M | $2.4M | $788,971 | $1.0M |
| Operating income | -$13.4M | -$7.3M | -$8.7M | -$8.6M | -$8.6M | -$8.4M | -$6.1M | -$6.3M | -$3.5M | -$3.1M |
| Interest expense | — | $23,793 | $13,319 | $44,677 | $97,630 | — | — | — | -$35,490 | -$2,400 |
| Net income | -$13.4M | -$7.8M | -$8.7M | -$8.8M | -$9.1M | -$11.5M | -$14.6M | -$10.0M | -$6.1M | -$5.8M |
| EPS (diluted) | $-4.23 | $-4.60 | — | — | — | — | — | — | — | — |
| Operating cash flow | -$4.3M | -$5.8M | -$7.1M | -$6.8M | -$2.6M | -$3.7M | -$5.0M | -$4.2M | -$2.5M | -$2.3M |
| Cash & equivalents | — | — | $1.8M | $8.9M | $137,862 | $346,111 | $388,891 | $317,135 | $506,986 | $16,589 |
| Total assets | $1.6M | $555,715 | $2.1M | $9.0M | $220,179 | $369,393 | $411,506 | $332,278 | $737,292 | $72,680 |
| Total liabilities | $2.2M | $2.8M | $2.1M | $2.9M | $11.5M | $8.7M | $22.7M | $16.6M | $14.4M | $9.6M |
| Shareholders' equity | -$514,898 | -$2.2M | -$10,622 | $6.0M | -$11.3M | -$8.3M | -$22.3M | -$16.3M | -$13.6M | -$9.5M |
Growth · year-over-year
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +468.6% | — | — | -100.0% | — | — | — | — | — | — |
| Net income growth | — | — | — | — | — | — | — | — | — | -950.3% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001101026 · US · as of 2024-12-31. facts plus Stocktoria's own computed scores — not investment advice.